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Moreover, even with access to adequate medical care,
only 40% of patients with atrial fibrillation are actually
treated with anticoagulants.12,13 Thus even if one
resides in an area with adequate medical services, the
thromboembolic complications of atrial fibrillation
remain a major health problem.
During the past 11.5 years, we have surgically ablat-
ed atrial fibrillation in a substantial number of patients
who had prior strokes and transient ischemic attacks
(TIAs) caused by left atrial mural thrombi associated
with atrial fibrillation. These patients are at high risk for
having a subsequent stroke even if they undergo antico-
agulation. The fact that the remaining patients in our
series also had atrial fibrillation means that they were
also at a higher risk for having strokes than the general
population. Our analysis indicates that surgical inter-
vention with the maze procedure nearly eliminates the
risk of stroke, even in patients who have had repeated
episodes of thromboembolism related to atrial fibrilla-
tion preoperatively.
Methods
Between September 25, 1987, and March 25, 1999 (11.5
years), we performed the maze procedure in 306 patients for
the treatment of atrial fibrillation. The first 32 (10%) patients
R ecent studies have documented that 2.2 million peo-ple in the United States have atrial fibrillation and
that approximately 75,000 strokes occur in these
patients each year.1,2 Anticoagulation with warfarin
sodium (Coumadin) and, in some instances, with
aspirin therapy decreases the incidence of stroke caused
by atrial fibrillation.3-11 Unfortunately, although antico-
agulation is beneficial, it does not abolish the risk of
stroke associated with atrial fibrillation. Indeed, the
incidence of stroke in patients with atrial fibrillation
who undergo anticoagulation optimally with warfarin
sodium remains between 2% and 5% per year, depend-
ing on the patient’s associated risk factors.3-6,8,11
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IMPACT OF THE MAZE PROCEDURE ON THE STROKE RATE IN PATIENTS WITH ATRIAL 
FIBRILLATION
underwent the maze I procedure,14-17 the next 15 (5%) patients
underwent the maze II procedure, and the remaining 259
(85%) patients underwent the maze III procedure.16-18 In the
latter group 49 (19%) of the 259 patients had the maze III pro-
cedure performed by using minimally invasive techniques.
Of the 306 patients who underwent the maze procedure for
atrial fibrillation, 76% were men. Sixty-one percent of the
patients had paroxysmal (intermittent) atrial fibrillation for
an average of 8 years (range, 0.5-45 years) before surgery.
The other 39% of patients had chronic (continuous) atrial fib-
rillation for an average of 11 years (range, 0.3-39 years)
before surgery. No patient had responded to medical therapy
for atrial fibrillation, having been treated unsuccessfully with
an average of 5.2 drugs per patient (range, 3-13 drugs).
Surgical indications included arrhythmia intolerance in 75%
of patients, drug intolerance in 6% of patients, and previous
thromboembolic events in 19% of patients. Twenty-four (8%)
patients had previous cardiac surgery, meaning that the maze
procedure was performed as a reoperative procedure in these
patients. One-hundred sixteen patients had 134 concomitant
procedures along with the maze procedure, including mitral
valve surgery (64 patients), aortic valve surgery (10 patients),
coronary artery bypass surgery (41 patients), and procedures
for other types of acquired and congenital cardiac anomalies
(19 patients).
These surgical patients were divided into 2 groups: group 1
(n = 58) consisted of patients who had experienced at least 1
documented thromboembolic event before surgery, and group
2 (n = 248) consisted of patients who had not experienced any
known episode of thromboembolism before surgery. The pre-
operative thromboembolic events that were experienced by
the 58 patients in group 1 included frank stroke in 40 patients
and TIAs in 18 patients. Twelve of the 40 patients who had a
history of stroke had also undergone TIAs. Five of these 40
patients also had noncerebral thromboembolism before
surgery. Two patients had over 5 separate strokes during the
2 weeks before surgery, and as a result, the maze procedure
was performed as an urgent procedure after air ambulance
evacuation to our hospital. Of the 18 patients who had TIAs,
80% experienced more than one such episode before surgery.
Interestingly, despite the fact that all of the patients in group
1 had experienced at least one episode of systemic throm-
boembolism associated with their atrial fibrillation, only 76%
of them had undergone anticoagulation before surgery.
Postoperative anticoagulation regimen. Details of the
postoperative anticoagulation regimen are presented in Table I.
Permanent anticoagulation with warfarin sodium (n = 45).
We do not give warfarin sodium to patients undergoing the
maze procedure alone. All patients with any type of mitral
valve prosthesis underwent anticoagulation unless there was
a specific contraindication in a patient with a tissue mitral
prosthesis. All patients receiving mechanical aortic valve
prostheses, including the 3 Bentall procedures in this series,
underwent permanent anticoagulation. Miscellaneous indica-
tions included various combinations of procedures in which
one component of the procedure did not warrant permanent
anticoagulation while another component did.
No long-term anticoagulation with warfarin sodium (n =
220). The patients who did not undergo permanent anticoag-
ulation after the maze procedure can be divided into 2 sub-
groups. The first subgroup (n = 78) underwent temporary
anticoagulation for 3 months. This subgroup included all
patients who had a history of having had a thromboembolic
event preoperatively (n = 58). The decision regarding whether
to use anticoagulants with these patients and for what period
of time was entirely empirical. The reasons for temporarily
using anticoagulants with the other 20 patients were varied.
When we first began the series in 1987, we routinely used
anticoagulants with all patients undergoing the maze proce-
dure for 3 months postoperatively, but that practice was dis-
continued in 1991. Throughout the series there have been a
few patients in whom early resistant perioperative atrial fib-
rillation has developed for whom we have elected to use anti-
coagulants. These patients have all converted out of atrial fib-
rillation before being discharged from the hospital, but we
have elected to continue giving them warfarin sodium for 3
months. Thereafter they all continue taking aspirin unless
there is a specific contraindication to doing so.
The second subgroup (n = 142) underwent no postoperative
anticoagulation with warfarin sodium. This is the largest sub-
group in the series because it includes all patients who
underwent the maze procedure only, except for those with a
history of previous thromboembolism. It also includes those
patients who underwent the maze procedure combined with
mitral valve repair, coronary artery bypass surgery, and tissue
aortic valve replacements who had no other concomitant pro-
cedure that would have dictated the necessity for anticoagu-
lation. These patients routinely received aspirin therapy
unless there was a specific contraindication to doing so.
Results
Operative results. The overall operative mortality
rate in this series of patients was 3.3%. Only one peri-
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Table I. Postoperative anticoagulation regimen for
patients undergoing the maze procedure for atrial
fibrillation
Permanent anticoagulation with warfarin sodium 45
All mitral valve replacements
Mechanical aortic valve replacements
Bentall procedures
Miscellaneous indications and combinations
No long-term anticoagulation with warfarin sodium 220
Temporary anticoagulation with warfarin sodium (78)
All patients with history of TE
Early patients in series
Miscellaneous indications
No postoperative anticoagulation with warfarin sodium (142)
Maze procedure only
Coronary artery bypass grafting
Mitral valve repair
Tissue aortic valve replacements
operative death occurred as a result of the maze proce-
dure itself, a delayed tamponade 9 days after surgery.
The remaining deaths occurred in patients undergoing
concomitant surgery for associated cardiac conditions,
including hypertrophic obstructive cardiomyopathy (2
patients), respiratory insufficiency caused by black lung
disease and amiodarone toxicity (2 patients), double-
valve surgery (1 patient), redo double-valve surgery (1
patient), mitral valve combined with coronary artery
bypass surgery (1 patient), redo mitral valve surgery (1
patient), and redo constrictive pericarditis surgery (1
patient). The most common perioperative complication
after the maze procedure is the development of tempo-
rary postoperative atrial fibrillation in 42% of patients.
Interestingly, this figure has dropped to 22% in the past
year, probably because the majority (70%) of the maze
procedures are now performed by using minimally inva-
sive techniques. As previously reported, the develop-
ment of perioperative atrial fibrillation has no adverse
effect on the long-term success rate of the maze proce-
dure in curing atrial fibrillation.17-21
A total of 265 patients have been followed between 3
months and 11.5 years (mean, 3.7 ± 2.9 years) after
surgery (Table II). After allowing each patient 3 months
to heal from the operation, all antitachycardia medica-
tions (if they had been instituted postoperatively) were
discontinued. Any subsequent documented episode of
atrial flutter or atrial fibrillation was classified as a
recurrence, even if it was only a single episode.
According to this rather stringent criterion, the recur-
rence rate was 5% for all maze patients, but it was only
1.8% in the 222 patients who had undergone the maze
III procedure more than 3 months previously. All
patients with recurrences were converted out of atrial
fibrillation and have remained in a regular rhythm. All
but 2 patients have required only one drug to maintain
the regular rhythm. Thus at the time of this update, 95%
of all patients have been cured of atrial fibrillation by
the maze procedure alone, and the other 5% of patients
have been cured with a combination of the maze proce-
dure and postoperative antitachycardia drugs. After the
maze III procedure, which has been used exclusively
since April 1992, 98.2% of patients have been cured
with surgery alone, and only 1.8% have required post-
operative antiarrhythmic medications. Currently, no
patient who has undergone the maze procedure has
either atrial fibrillation or atrial flutter.
Stroke rate in patients undergoing the maze pro-
cedure. Stroke rates in patients undergoing the maze
procedure are shown in Table III. During the perioper-
ative period, one patient in group 1 (1.7%) and one
patient in group 2 (0.4%) had a stroke. In these 2
patients who had perioperative strokes, there remains a
left foot drop in one patient at 9 years and mild resid-
ual weakness on the left side in the other at 5 months.
During the subsequent 11.5 years of follow-up, there
were no strokes in group 1 patients and only one minor
stroke in group 2 patients. Thus the overall stroke rate
in all patients undergoing the maze procedure was
0.7% in the perioperative period and 0.4% in the fol-
low-up period of 11.5 years.
TIA rate in patients undergoing the maze proce-
dure. TIA rates in patients undergoing the maze proce-
dure are shown in Table IV. During the perioperative
period, one patient in group 1 (1.7%) and one patient in
group 2 (0.4%) had a TIA. The 2 perioperative TIAs
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Table II. Number of patients available for evaluation of late results
Total followed 
Total No. of patients Operative deaths Followed <3 mo Late deaths long-term
Group 1 58 2 6 0 50
Group 2 248 8 19 6 215
Total 306 10 25 6 265
Table III. Stroke rate during the perioperative period
and on late follow-up for patients undergoing the maze
procedure
Group 1 Group 2 Total
Perioperative 1.7% (n = 58) 0.4% (n = 248) 0.7% (n = 306)
(<3 mo)
Follow-up 0% (n = 50) 0.5% (n = 215) 0.4% (n = 265)
(3 mo-11.5 y)
Table IV. Rate of TIAs during the perioperative peri-
od and on late follow-up for patients undergoing the
maze procedure
Group 1 Group 2 Total
Perioperative 1.7% (n = 58) 0.4% (n = 248) 0.7% (n = 306)
(<3 mo)
Follow-up 2% (n = 50) 0.5% (n = 215) 0.8% (n = 265)
(3 mo-11.5 y)
were treated with anticoagulation for 3 months with no
subsequent events.
During the subsequent 11.5 years of follow-up, there
was one TIA in group 1 (2.0%) and one TIA in group 2
(0.5%). The 2 patients who had late TIAs were imme-
diately anticoagulated and have remained so now for up
to 8 years. Neither patient has had any further throm-
boembolic events. Thus the TIA rate in all patients
undergoing the maze procedure was 0.7% in the peri-
operative period and 0.8% in the follow-up period of
11.5 years.
Analysis of results by clinical category
Atrial fibrillation with no associated risk factors.
This group includes lone atrial fibrillation, a term that
generally refers to patients who have atrial fibrillation
with no other detectable cardiac abnormalities, but it
may also include patients with associated cardiac
anomalies that do not represent positive risk factors for
stroke. The stroke rate in this group of patients is only
1% per year, even without anticoagulation.8,11 It is for
this reason that these patients are not usually anticoag-
ulated in clinical practice.
In our series 162 patients corresponded to this cate-
gory, and surprisingly, 81 (50%) of them had under-
gone anticoagulation at the time they presented to us.
After the maze procedure, none of these patients
received long-term anticoagulation, and only one
minor stroke occurred during the follow-up period of
3.8 ± 3.0 years. 
Atrial fibrillation with associated risk factors but no
previous stroke or TIA. Several studies have document-
ed the major risk factors associated with an increased
likelihood of having a stroke caused by atrial fibrilla-
tion. These include advanced age, hypertension, dia-
betes mellitus, previous stroke or TIA, congestive heart
failure, and ischemic heart disease.8,11 The stroke rate
associated with one or more of these risk factors and
atrial fibrillation is 6% to 8% per year in patients not
undergoing anticoagulation and 2% per year in patients
undergoing adequate anticoagulation. In our series 86
patients were in this category, and they had a follow-up
period of 3.1 ± 2.9 years. Forty-six percent of these
patients underwent anticoagulation preoperatively, and
54% did not undergo anticoagulation. This pattern of
anticoagulation in these high-risk patients is consistent
with previous reports indicating that only 40% of such
patients actually receive anticoagulation.12,13 None of
our patients in this category had strokes postoperatively.
Atrial fibrillation with associated risk factors includ-
ing previous stroke or TIA. The incidence of stroke in
patients in this category is 12% per year if the patient
has not undergone anticoagulation8,9,11 and 5.1% per
year if the patient has undergone anticoagulation.8 In
our series 58 patients corresponded to this category.
Forty-four patients had undergone anticoagulation, and
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Table V. Perioperative stroke rates for the major
categories of cardiac surgical procedures
Percent Percent Percent 
permanent transient total 
Surgical procedure stroke stroke strokes
CABG + MVR 4.17% 1.73% 5.90%
CABG + AVR 3.40% 1.60% 5.00%
CABG + MV repair 3.12% 1.41% 4.53%
AVR + MVR 2.73% 1.51% 4.24%
MV repair 1.85% 1.45% 3.30%
MVR 2.28% 0.98% 3.26%
AVR 1.73% 1.23% 2.96%
CABG 1.69% 0.75% 2.44%
Maze ± other 0.65% 0% 0.65%
CABG, Coronary artery bypass grafting; MVR, mitral valve replacement; AVR,
aortic valve replacement; MV, mitral valve.
Fig 1. Stroke rate curves for patients with atrial fibrillation
treated nonsurgically3-13 compared with patients with atrial
fibrillation treated with the maze procedure. The curves are
described below as beginning at the top curve and progress-
ing downward to the bottom curve. Top curve, Atrial fibrilla-
tion, positive risk factors, previous thromboembolism, no
anticoagulation; second curve, atrial fibrillation, positive risk
factors, no previous thromboembolism, no anticoagulation;
third curve, atrial fibrillation, positive risk factors, previous
thromboembolism, anticoagulation; fourth curve, atrial fibril-
lation, positive risk factors, no previous thromboembolism,
anticoagulation; fifth curve, atrial fibrillation, no risk factors,
no previous thromboembolism, no anticoagulation; bottom
curve, After the maze procedure.
14 patients had not undergone anticoagulation at the
time they presented to us. The follow-up period for this
group of patients, in which no postoperative strokes
occurred, was 3.7 ± 2.5 years.
Discussion
Perioperative stroke rate. One of the major con-
cerns when we first began to perform the maze proce-
dure clinically in 1987 was that the incidence of peri-
operative stroke in these patients, many of whom had
already had a thromboembolic event, would be sub-
stantially higher than that associated with other types
of cardiac surgery. Much to our surprise, the exact
opposite has been the case (Table V). The 1998 data
from the National Database for Adult Cardiac Surgery
published by the Society of Thoracic Surgeons docu-
ment that the perioperative stroke rate is higher for
every major cardiac surgery procedure than it is for the
maze procedure.22
One explanation for the paradox of having the lowest
perioperative stroke rate in patients who might be
expected to have the highest is that the average age of
the patients in this series was substantially less than the
average age of patients in most reported cardiac surgi-
cal series. It is our suspicion that in addition to the age
factor, the absence of a left atrial appendage postoper-
atively probably contributes to the low perioperative
stroke rate.
Long-term postoperative stroke rate. Follow-up in
these patients is an ongoing project and is accom-
plished either by direct patient contact or through con-
tact with one of the referring physicians. The maze pro-
cedure not only reduced the rate of stroke in all
categories of patients but nearly abolished the risk of
stroke postoperatively (Fig 1). By using the published
stroke rates for the various categories of patients, it
would appear that at a mean of 3.9 years after surgery,
the maze procedure has thus far prevented strokes that
would have occurred in approximately 29 patients had
the surgical procedure not been applied.
To understand why the maze procedure is so effective
in reducing the incidence of stroke associated with atri-
al fibrillation, it is helpful to review some of the salient
points about thromboembolism associated with atrial
fibrillation. It is sometimes not appreciated that both
atria are fibrillating during atrial fibrillation. This rais-
es the question as to why systemic embolization from
thrombi formed in the left atrium are so much more
common than pulmonary embolization from thrombi
that might logically form in a similar manner in the
right atrium. Clinical experience, however, documents
that although left atrial thrombi are a common occur-
rence in atrial fibrillation, right atrial thrombi are not.
Differences in the right atrial and left atrial anatomy
probably explain these clinical patterns. For example,
the orifice of the right atrial appendage is so broad-
based that it is not usually thought of as being an ori-
fice at all. Moreover, this wide-open entrance into the
relatively shallow right atrial appendage is located
immediately adjacent to the stream of blood flow from
the superior vena cava into the right atrium and across
the tricuspid valve. Therefore there is little opportunity
for stasis of blood within the body of the right atrial
appendage, even when the atrium is fibrillating. On the
contrary, the orifice of the left atrial appendage is an
identifiable anatomic opening in virtually all patients.
This narrow orifice leads into a relatively long narrow
lumen of the left atrial appendage, which is eccentric to
the stream of blood flow from the pulmonary veins to
the mitral valve. Therefore when the atrium is fibrillat-
ing, severe stasis of blood in the left atrial appendage is
virtually assured and is one of the major factors result-
ing in thrombus formation in the left atrial appendage.
Perhaps the major reason for the maze procedure’s
protective effect against thromboembolism is that it
cures the atrial fibrillation. Our studies have document-
ed that postoperatively the left atrium functions well in
93% of patients and the right atrium functions essen-
tially normally in 98% of patients.21 This restoration of
atrial contractile function in both atria in over 90% of
patients is clearly an important factor in reducing post-
operative stasis of blood flow and hence in reducing the
likelihood of the formation of atrial thrombi. Un-
doubtedly, another reason for the absence of strokes
after the maze procedure is the fact that the left atrial
appendage is either excised or its orifice is surgically
closed as a part of the surgical procedure. This means
that after the maze procedure, there is no atrial fibrilla-
tion, there are no atrial appendages, and the atria are
contracting. Thus there is no reason for atrial thrombi
to form unless there is an underlying hypercoagulabili-
ty syndrome in which case the surgically altered left
atrium should theoretically be no more likely to harbor
mural thrombi than any other nearby structure, such as
the pulmonary veins or the left ventricle.
Another question is whether the 7% of patients with
no demonstrable left atrial contractile function after the
maze procedure should undergo anticoagulation. We
have not done so for the following reasons. All of these
patients have essentially normal function of the right
atrium and normal right atrial to right ventricular syn-
chrony. This results in a normal right-sided cardiac out-
put that is delivered to the left side of the heart through
the pulmonary circulation. In the presence of a reason-
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ably normal left ventricle, studies have shown that it
makes no difference whether the left atrium is contract-
ing because the left ventricle will immediately adapt to
the normal right-sided output that has just been deliv-
ered to it.23 The volume of flow through the left atrium
remains normal, the left ventricular filling is regular,
and there is no left atrial appendage to serve as a nidus
for thrombus formation. Thus there is no reason to sus-
pect that systemic thromboembolism would be any
higher in these patients than it is in those patients with
demonstrable left atrial contraction. This is also the rea-
son why we have never placed any particular impor-
tance on the magnitude of left atrial contraction after
the maze procedure, although it is clearly more esthet-
ically pleasing to have it present postoperatively.
In summary, the maze procedure has proven to be
very effective in abolishing the threat of a stroke asso-
ciated with atrial fibrillation without the need for anti-
coagulation. The data presented in this study raise the
question of whether the surgical indications for the
maze procedure should be expanded to include the pre-
vention of stroke.
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Discussion
Dr Hartzell V. Schaff (Rochester, Minn). This follow-up of
306 patients focuses on late stroke but also provides some
important information on the persistent benefit of the maze
procedure in eliminating the recurrence of atrial fibrillation in
a follow-up that extends to 11 years.
The report of only 2 perioperative neurologic events, a risk
of 0.7%, and one late stroke is striking. In his article Dr Cox
stratifies this large patient group according to preoperative
clinical characteristics to provide some yardstick against
which surgical results can be measured. One hundred sixty-
two (53%) patients had paroxysmal or chronic atrial fibrilla-
tion with no additional risk factors, and as mentioned, the risk
of stroke in this group is so low that anticoagulation is not
necessary. Therefore clearly the maze procedure would not
be indicated. Eighty-six (28%) patients had no previous cere-
brovascular accidents but were considered at high risk
because of the presence of additional risk factors, and the
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question of whether the maze procedure might be indicated to
prevent stroke in this group is still unsettled.
Our own experience supports the conclusion that the maze
procedure does reduce the risk of thromboembolic stroke,
and over a 6-year period, from 1993 through 1998, we per-
formed the operation in 212 patients. There have been 2
deaths early after surgery, yielding a perioperative mortality
rate of approximately 1%, and atrial fibrillation was abol-
ished in 90% of patients.
Our experience differs somewhat from that of Dr Cox in
that 76% of our patients had concomitant procedures, and
70% of these were mitral valve repairs. In an effort to learn
whether the addition of the maze procedure to the mitral
valve repair reduced risk of postoperative stroke, we com-
pared 39 patients who had the combined operation to 58
patients who had mitral valve repair with atrial fibrillation. 
During a follow-up period extending to 3 years, 4 patients
in the control group had a stroke or TIA, and 4 patients had
bleeding complications caused by warfarin sodium. The dif-
ference in the risk of stroke approached statistical signifi-
cance, but more important, when we combine the end point
of stroke and bleeding caused by anticoagulation, the reduc-
tion in events was statistically significant. We believe that the
restoration of sinus rhythm also protects the patients from the
hazards of bleeding and is an important issue. 
Dr Cox, I have several questions. The perioperative stroke
rate of 0.7% is lower than one would expect, as you point out,
for most surgical procedures, and yet over 40% of the patients
had recurrence of atrial fibrillation. This suggests that in
addition to the relatively young age, obliteration of the left
atrial appendage is an important mechanism in stroke reduc-
tion. I suppose if we carry this assumption to its logical con-
clusion, the question arises as to whether every patient under-
going cardiac surgery should have ligation of the left atrial
appendage, and I would appreciate your comments on this.
Along the same lines, you detail the protocol for anticoag-
ulation but did not mention antiplatelet therapy. Do you use
aspirin in the patients early, and if so, do you continue it?
If the operation can be performed at low risk, it surely
seems reasonable to recommend it for patients with prior
TIAs and thromboembolic events, especially those requir-
ing warfarin sodium for anticoagulation, but for patients
without preoperative neurologic events, the presence of
which risk factors for stroke would persuade you to advise
a maze operation? 
Finally, you emphasize the recent development of mini-
mally invasive surgery, and as I understand your procedure,
interruption of the left atrial conduction pathway is accom-
plished by cryolesions. We have noticed, in postoperative
echocardiographic studies, a fairly uniform reduction in left
atrial size caused by simple incision and suture. Do you
believe that reducing the size of the left atrium is an impor-
tant byproduct of the procedure, and if so, do you exclude
patients from minimally invasive procedures who have
enlarged left atria? 
Dr Cox. Thank you, Dr Schaff. As usual, I expected and
received a very erudite discussion of this problem, and I
appreciate your comments very much.
In terms of the perioperative stroke rate, I do believe that
the fact that these patients were younger is important.
However, I also believe that ligation of the left atrial append-
age is critical in preventing early and late strokes in these
patients. Whether we should do this on all patients is ques-
tionable, but a prospective study of, for example, patients
undergoing coronary bypass, in whom left atrial ligation is
prospectively randomized, seems to me to be a reasonable
proposition. 
Your question also raises the issue of how many periopera-
tive strokes are caused by atrial fibrillation as opposed to ath-
erosclerosis of the ascending aorta or other causes. I believe
that atherosclerosis is the major cause of strokes in cardiac
surgery patients. However, Dr Larry Creswell wrote a paper
a few years ago from our group in St Louis showing that the
perioperative stroke rate is higher in patients with postopera-
tive atrial fibrillation. Nevertheless, before I would recom-
mend routine atrial appendage ligation in all cardiac surgery
patients, I would prefer to see a prospective randomized trial.
In answer to your second question regarding aspirin use,
we routinely give aspirin to these patients postoperatively if
they do not require warfarin sodium for other reasons, such as
mechanical valve replacement. I did not mention the effects
of aspirin on the incidence of stroke, but as you know, it also
has a beneficial effect in some patients. Whether we keep
those patients on aspirin beyond 3 months is really left to the
patient. We do not require that they continue aspirin beyond
that time.
Your next question related to the importance of reducing
the size of the left atrium. I do not think that left atrial size is
important if one performs the standard maze procedure in
which multiple incisions are made because one can trim the
atrium down in size before closing the incisions. In addition,
even though the minimally invasive approach that we now
use routinely requires fewer incisions, I would not exclude
someone from minimally invasive surgery on the basis of a
large atrium. If we have a patient with a large left atrium, I
extend the length of the incision between the pulmonary
veins and the mitral valve much further into the left atrium
than normal and then trim each side of the incision before
closing. The optimal place to decrease the size of the large
left atrium is between the pulmonary veins and the mitral
valve anulus.
Finally, you asked a question about which risk factors
other than thromboembolism I would include as indications
for performing the maze procedure. If a patient has one or
two of the risk factors and has undergone adequate anticoag-
ulation but has had atrial fibrillation for several years, the
risk of stroke becomes formidable. For example, if a patient
has positive risk factors and no previous history of throm-
boembolism but then has a TIA, that patient must undergo
anticoagulation. Even with anticoagulation, 50% of those
patients will have a stroke in 12 years, which was the dura-
tion of this study. Thus if a patient has had atrial fibrillation
for 6 or 7 years and is worried about a stroke, even though
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otherwise normal, I would consider performing a minimally
invasive maze procedure in view of the results presented
today. I would hasten to add, however, that in patients with
lone atrial fibrillation who are at low risk of having a stroke,
we do not perform the maze procedure because of the threat
of a stroke.
Your comment about considering both bleeding from war-
farin sodium and thromboembolic stroke in analyses such as
this is a very important one. We elected not to confuse the
issue of thromboembolic strokes with hemorrhagic strokes
caused by anticoagulation in this study. Clearly, including the
incidence of hemorrhagic strokes in patients receiving war-
farin sodium would have increased all the numbers in this
study and would have made an even stronger argument for
permanently ablating atrial fibrillation and the risk of stroke,
even if it means undergoing a surgical procedure.
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